Just over one and a half years into our exciting collaboration with Roche and Genentech, we have reached the first of what we expect to be many formal milestones together.
After building fit-for-purpose oncology maps for our partner spanning whole-genome arrayed CRISPR knockouts and hundreds of thousands of small molecules, we have identified and validated the first hit series for this particular disease, and our partner Roche has exercised the Small Molecule Validation Program Option. Our teams at Recursion will continue to take the lead in advancing the program, leveraging the Recursion OS and our suite of digital chemistry tools with the support and collaboration of our partner.
This milestone represents a critical step in our joint efforts to initiate and advance new therapeutic programs using our Maps of Biology and Chemistry. The work to purpose-build maps of biology in this specific area of oncology is followed by additional, exciting work to build similar maps across multiple CNS cell types that we hope will lead to many novel target hypotheses and partnered therapeutic programs in the near future.
To learn more about the structure and progress of this expansive partnership, watch the video below and read more on Genentech’s “Beyond the Deal” editorial series.
